| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5536488 | Vaccine | 2017 | 6 Pages |
Abstract
The discounted cost per DALY averted was less than the GDP per capita for nearly all scenarios considered, indicating that a routine rotavirus vaccination program is highly likely to be cost-effective. Even in a low mortality setting with no Gavi subsidy, rotavirus vaccination would be cost-effective. These estimates exclude the herd immunity benefits of vaccination, so represent a conservative estimate of the cost-effectiveness of rotavirus vaccination in Bangladesh.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Clint Pecenka, Umesh Parashar, Jacqueline E. Tate, Jahangir A.M. Khan, Devin Groman, Stephen Chacko, Md Shamsuzzaman, Andrew Clark, Deborah Atherly,